CROI 2020 – Single-tablet bictegravir+emtricitabine+tenofovir alafenamide non-inferior to dolutegravir-based regimens in older adults with HIV

  • Liz Scherer
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.


  • In a study presented at this year’s Conference on Retroviruses & Opportunistic Infections (CROI – 2020), the single-tablet antiretroviral treatment (ART) regimen comprising bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) appears to be non-inferior to both dolutegravir, abacavir, and lamivudine (DTG/ABC/3TC), and dolutegravir, and tenofovir alfenamide (DTG+F/TAF) in older (ages 50+), treatment-naïve adults living with HIV.

Why this matters

  • Single-tablet B/F/TAF may represent an alternative, safe, and well-tolerated HIV treatment strategy in older adults.
  • Single-tablet regimens have been shown to boost adherence rates.

Key results

  • 196 patients/1274 in final analysis (629 enrolled in 1st study, 645 in 2nd).
  • Most participants were male (73%-92%), roughly one-third (20%-37%) were black or of African descent.
  • At enrollment, 80%-90% of patients had median CD4 405-534 cells µ/mL.
  • At week 144, 81% of B/F/TAF >50 years reached virologic suppression vs 83%, 88% of younger DTG/ABC/3TC, DTG+F/TAF groups, respectively, demonstrating non-inferiority.
  • Similar results were observed in patients aged 
  • No treatment-emergent resistance observed to any components.
  • Regimens did not have any clinically significant impact on renal safety; while slight hip bone mineral density declines were observed in both groups, changes were comparable between older, younger patients.
  • Median weight increases ranged from 3.4 kg to 5.3 kg for older and younger patients respectively, taking DTG+F/TAF.

Study design

  • Pooled data analysis of two phase 3 randomised, double-blind studies comparing single-tablet B/F/TAF to DTG/ABC/3TC in older, treatment-naive adults living with HIV. Pooled analysis assessed safety, efficacy at week 144.
  • Funding: Gilead Sciences, Inc.


  • Limited generalisability.


“There were no clinically significant differences in median changes from baseline to fasting lipids,” among those aged 50 and older, noted Dr Mills and associates.